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Abstract Biallelic germline mutations of MUTYH—a
gene encoding a base excision repair protein—are asso-
ciated with an increased susceptibility of colorectal
cancer. Whether monoallelic MUTYH mutations also
increase cancer risk is not yet clear, although there is
some evidence suggesting a slight increase of risk. As the
MUTYH protein interacts with the mismatch repair
(MMR) system, we hypothesised that the combination
of a monoallelicMUTYH mutation with an MMR gene
mutation increases cancer risk. We therefore investi-
gated the prevalence of monoallelic MUTYH mutations
in carriers of a germline MMRmutation: 40 carriers of a
truncating mutation (group I) and 36 of a missense
mutation (group II). These patients had been diagnosed
with either colorectal or endometrial cancer. We com-
pared their MUTYH mutation frequencies with those
observed in a group of 134 Dutch colorectal and endo-
metrial cancer patients without an MMR gene mutation
(0.7%) and those reported for Caucasian controls
(1.5%). In group I one monoallelic MUTYH mutation
was found (2.5%). In group II ﬁve monoallelic germline
MUTYH mutations were found (14%), four of them in
MSH6 missense mutation carriers (20%). Of all patients
with an MMR gene mutation, only those with a mis-
sense mutation showed a signiﬁcantly higher frequency
of (monoallelic) MUTYH mutations than the Dutch
cancer patients without MMR gene mutations
(P=0.002) and the published controls (P=0.001). These
results warrant further study to test the hypothesis of
mutations in MMR genes (in particular MSH6) and
MUTYH acting together to increase cancer risk.
The MUTYH protein is a base excision repair
(BER) DNA glycosylase that excises misincorporated
adenines opposite 8-oxo-7,8-dihydro-2¢-deoxyguanosine
(8-oxoG), which is a product of oxidative DNA damage
(Slupska et al. 1999). Recently, it has been shown that
having germline mutations in both copies (i.e. biallelic)
of the MUTYH gene, increases the risk to develop
multiple adenomatous polyps and, hence, colorectal
cancer (Al Tassan et al. 2002). Whether monoallelic
MUTYH mutations also increase cancer risk is not yet
clear, although there is some evidence suggesting a slight
increase of risk (Croitoru et al. 2004; Farrington et al.
2005). It is conceivable that germline monoallelic
MUTYH mutations combined with germline mutations
in other genes more strongly increase cancer risk.
Germline mutations of MLH1, MSH2 and MSH6 in
combination with (functional) loss of the wild-type allele
are known to cause a deﬁcient DNA mismatch repair
(MMR) system, and are responsible for hereditary
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non-polyposis colorectal cancer (HNPCC). HNPCC is
one of the most common inherited cancer syndromes
and is characterised by susceptibility to develop colo-
rectal cancer and extracolonic malignancies, in particu-
lar endometrial cancer (Lynch and de la Chapelle 2003).
Gu et al. (2002) demonstrated that the MUTYH
protein interacts with the MMR protein MSH6 which is
part of the MSH2/MSH6 heterodimer (hMutSa). They
showed that hMutSa stimulates the DNA binding and
glycosylase activities of MUTYH. In addition, it was
shown that the interaction between MUTYH and
MSH6 was weaker in cells that expressed wild-type
MSH2 and MSH6 missense mutations (Gu et al. 2002).
Considering this interaction between the MUTYH and
MSH6 proteins, and assuming that part of (familial)
cancer cases might be explained by combinations of low-
penetrant germline mutations in known hereditary can-
cer genes, we hypothesised that a monoallelic MUTYH
mutation might contribute to cancer susceptibility in
carriers of an MMR gene (in particular MSH6) muta-
tion. This might be most apparent in the case of mis-
sense MMR gene mutations, that in contrast to
truncating mutations, ‘‘on their own’’ may result in a
less severely impaired MMR system and may therefore
less strongly contribute to cancer risk.
As a ﬁrst step to test this hypothesis, we investigated
the prevalence of monoallelic MUTYH mutations in
patients diagnosed with colorectal and/or endometrial
cancer who carried a truncating or missense MMR gene
mutation inMLH1,MSH2 orMSH6. We compared the
frequencies of monoallelic MUTYH mutations in the
two groups with that in a third group of patients, with
colorectal and/or endometrial cancer without an MMR
gene mutation and with the frequency of monoallelic
MUTYH mutations reported for controls.
Materials and methods
Patient inclusion
In our study we included 210 unrelated colorectal and/or
endometrial cancer patients (Table 1). Each patient had
recently been tested for germline MMR gene mutations
in one of four diﬀerent genetic centres, i.e. the University
Medical Center Groningen (n=172), the Radboud
University Nijmegen Medical Center (n=24), the
Netherlands Cancer Institute in Amsterdam (n=5) and
the Leiden University Medical Center (n=9), because
they had an increased risk for HNPCC, e.g. early-onset
cancer, multiple HNPCC associated tumours, or a po-
sitive family history for these tumours. Seventy-six pa-
tients had a proven germline mutation in one of the
MMR genes MLH1,MSH2 and MSH6 (36 missense en
40 truncating mutation carriers) and 134 patients had no
MMR gene mutation. All patients had given their in-
formed consent and the study was approved by the
Medical Ethical Committee of the University Medical


















































































































































































































































































































































































































































































































































































































































































































































































MUTYH mutation frequency in control population
Presently, no large groups of healthy Dutch controls
have been screened for the entire MUTYH gene. Thus,
the DutchMUTYH mutation frequency is yet unknown.
Therefore, data were taken from the only two studies in
which the entire MUTYH gene of control individuals
had been screened for mutations. Together, these studies
reported 7 monoallelic MUTYH mutations in 461 con-
trols from the British Isles [1.5% (95% CI 0.61–31)]
(Sieber et al. 2003; Fleischmann et al. 2004).
Genetic analysis
For the mutation analysis in the MMR genes diﬀerent
techniques had been used: denaturing gradient gel elec-
trophoresis (DGGE), single-strand conformational
polymorphism analysis, direct sequencing and multiplex
ligation dependent probe ampliﬁcation, as described
previously (Wu 1999; Gille et al. 2002).
Mutation analysis of MUTYH in DNA from
peripheral blood lymphocytes was performed for 201
patients by DGGE combined with direct sequencing of
PCR fragments showing aberrant patterns in DGGE.
polymerase chain reaction (PCR) was performed in a
total reaction volume of 50 ll containing 200 ng of
DNA, 15 pmol of each primer (Eurogentec, Serain,
Belgium), 0.2 ll rTaq polymerase (5,000 U/ml, Amer-
sham Pharmacia Biotech Inc., Biscataway, NY, USA),
5 ll DMSO (Sigma, Taufkirchen, Germany) and 5 ll
PCR buﬀer (Amersham Biosciences, Roosendaal,
Netherlands). The primer sequences are described in
Table 2.
A stepdown cycling regime was performed in an
Applied Biosystems GeneAmp 9700 Thermal Cycler
(Foster City, USA) using the following conditions: ini-
tial denaturation for 3 min at 94C, followed by ﬁve
cycles of 1 min at 94C, 1 min at 60C and 1 min at
72C. Hereafter ﬁve more cycles with an annealing
temperature of 57C and 30 cycles with an annealing
temperature of 54C were performed. Finally, 5 min
elongation at 72C. PCR products were checked on a
2% agarose gel. PCR products with diﬀerent melting
temperatures were pooled in six diﬀerent pools and PCR
products were denaturated at 96C for 10 min and re-
annealed at 50C for 45 min before gel electrophoresis
to encourage the formation of heteroduplex molecules.
For DGGE analysis ofMUTYH, a 30 ll pooled sample
was applied onto a 1-mm-thick 9% polyacrylamide
(PAA) gel (acrylamide:bisacrylamide=37.5:1) contain-
ing a denaturating gradient of 40–85% urea-formamide
(100% urea-formamide contains 7 mol/l urea and 40%
deionised formamide). Electrophoresis was performed in
Table 2 Primer sequences for mutation analysis in MUTYH




1 F [60GC] CTTCCCCTCTCCCAGAGC 293 81.7
R [CGCCGC] GACGTCTGAACGGAAGTTCG
2 F [40GC] CCCTTGGAAGGCCTCAAAAT 294 75.9
R [CGCGCGCG] CCAGCCTGAATCTGCCTTTC
3 F [CGC] CTGTGTCCCAAGACCCTGAT 299 76.5
R [40GC][ATATATAT] CACCCACTGTCCCTGCTC
4 F [40GC][ATATATAT] ACCATGGAGAAGACGGGTAG 299 77.4
R [CGCGC] GGTTGGCATGAGGACACTG
5,6 F GTAGGGGCAGGTCAGCAGT 394 75.1
R [40GC] TCACCCGTCAGTCCCTCTAT
7 F [CGCCCG] CGGGTGATCTCTTTGACCTC 248 75.8
R [40GC] CCCCCTAGCTCCTCTACCAC
8 F [40GC] CCAGGAGTCTTGGGTGTCTT 280 77.8
R AGAGGGGCCAAAGAGTTAGC
9 F [CGCCC] CAGCCCAGGCTAACTCTTTG 233 78.0
R [40GC] AGCAGAGCTCCTTTGCAGAC
10 F [CGCGCGCGCG] GTGTCTGCAAAGGAGCTCTG 308 78.5
R [50GC] CATAGGGCAGAGTCACTCCTTAG
11 F [40GC] GGGGCAGTGAGAAGTCCTAAG 239 77.1
R [CGCCCG] AAGAACTGGAATGGGGCTTC
12 F [CGCCCG] CCTAAAGCCCTCTTGGCTTG 346 77.9
R [40GC] CCGATTCCCTCCATTCTCTC
13 F [CGCGCGC] AAGAGAGAATGGAGGGAATCG 292 79.4
R [60GC] TAGCCTCAAAAGCCAACATC
14a F [40GC] CACCTTGGGGAGGTAAGTGA 202 74.0
R [CGCGCGCGCG] AGGCCAGCCCATATACTTGA
14b F [CGCGCGCG] CCAGGTTGTCCACACCTTCT 255 75.9
R [40GC] GAACATGTAGGAAACACAAGGAA
15 F [CGCCC] AAAAAGTGCCAGCCCTCAC 237 73.8
R [40GC] AGTGAAGCCTGGAGTGGAGA
16 F [CGCCC]CCCTCCCCCAACTACAAGG 266 75.0
R [40GC] TTTACTAACAACAGGATTCTCAGG
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0.5·TAE (1·TAE = 40 mM Tris, HAC pH 8.0; 20 mM
NaAc; 1 mM Na2EDTA), at 120 V/19 cm, for 16 h at
62C for exons 1 and 13 and at 60C for the other exons
using an INGENYphorU system (Ingeny International,
Goes, The Netherlands). The gel pattern was visualised
by ethidiumbromide staining for 10 min and UV trans-
illumination of the gel. Exons displaying variant gel
patterns were ampliﬁed again from genomic DNA with
primers containing a universal M13 tail (forward primer:
cgacgttgtaaaacgacggccagt, reverse primer: caggaaacagc-
tatgac), cycle sequenced in both directions with dye la-
belled primers (Big Dye Terminator v3.1 Sequencing
Kit, Applied Biosystems, Foster City, USA). In nine
patients only exons 6–13 were screened by direct
sequencing. Whenever, a sequence variant was detected,
200 control chromosomes of anonymous healthy Dutch
individuals were screened for this variant.
Microsatellite instability analysis
MSI analysis was performed as described previously
(Berends et al. 2002). Cancers were classiﬁed as MSI-
high when two or more markers showed MSI and as
MSI-low when one or no marker showed MSI. As a
limited number of markers was analysed, the classiﬁca-
tion microsatellite-stable is not used.
Immunohistochemistry
Immunohistochemistry for the MLH1, MSH2 and
MSH6 proteins was performed as previously described
(Berends et al. 2002). Protein expression in normal tissue
adjacent to the cancer served as internal positive control.
The sections were scored as either negative (i.e., absence
of detectable nuclear staining of cancer cells) or positive
for MLH1, MSH2 and MSH6 staining. Scoring of the
staining was performed without knowledge of the MSI
or mutation status.
Statistical analysis
MUTYH mutation frequencies and two-sided 95% CI
intervals were calculated for the diﬀerent groups of
MMR gene mutation carriers. To compare these fre-
quencies with the frequency of monoallelic MUTYH
mutations in controls reported in the literature, and with
the frequency of monoallelic MUTYH mutations in
colorectal and/or endometrial cancer patients without
MMR gene mutation, crosstabs were constructed and
results were analysed by the Fisher’s Exact Test.
Results
One of the 134 cancer patients without an MMR gene
mutation carried anMUTYH mutation [0.7% (95% CI.
0.019–4.1%)]. Amongst the 36 missense MMR gene
mutation carriers, ﬁve monoallelic MUTYH mutations
were detected [14% (4.7–29%)]. This frequency was
signiﬁcantly diﬀerent from the MUTYH mutation fre-
quency in the group of cancer patients without an MMR
mutation (Pnon-mutation carriers=0.002), and from the
frequency (1.5%) in controls (Pcontrols=0.001). Inter-
estingly, four of the MUTYH mutations were found
amongst the 20 patients with an MSH6 missense
mutation [20% (5.7–44); Pnon-mutation carriers=0.001;
Pcontrols=0.001] and one mutation was found amongst
the ﬁve MSH2 missense mutation carriers [20% (0.51–
72); Pnon-mutation carriers=0.071; Pcontrols=0.083]. No
MUTYH mutations were found in DNA from any of 11
MLH1 missense mutation carriers [0% (0.0–35)]. In the
group of 40 truncating MMR gene mutation carriers a
single monoallelic MUTYH mutation was found [2.5%
(0.1–13); Pnon-mutation carriers=0.408; Pcontrols=0.489].
TheMUTYH mutation frequency in the group of cancer
patients without an MMR mutation, was not signiﬁ-
cantly diﬀerent from the 1.5% reported in British con-
trols (P=0.430). None of the MUTYH mutations was
detected in 200 control chromosomes. The results of the
mutation analysis are summarised in Table 3. In addi-
tion to theMUTYH mutations, several previously in the
normal population described polymorphisms were de-
tected. In the group of patients whereMUTYH (n=201)
was analysed by DGGE, the p.Val22Met (c.64G>A),
p.Gln324His (c.972G>C) and p.Ser501Phe
(c.1502C>T) polymorphisms were found with frequen-
cies of 12.4%, 29.9%, and 3.0%, respectively. In addi-
tion, a silent mutation p.Tyr90Tyr (c.270C>T) was
detected and various changes in non-coding sequences:
c.36+75C>G (0.5%), c.157+30A>G (6.5%),
c.346+56G>A (1.0%), c.462+35G>A (10.4%),
c.648+21C>A (1.0%), c.1145–27C>T (1.0%).
Discussion
In the present study we found a signiﬁcantly higher
frequency of monoallelic MUTYH mutations in
(MSH6) missense mutation carriers than in published
Caucasian controls and Dutch colorectal and endome-
trial cancer patients without MMR gene mutation.
We observed ﬁve diﬀerent MUTYH mutations: four
missense mutations, one splice site mutation. Of these,
the p.Gly382Asp and p.Tyr165Cys missense mutations
are the two most common pathogenic MUTYH mis-
sense mutations found in patients with multiple adeno-
matous polyps. The sequence change caused by the
mutation c.36+1G>A interferes with the splice donor
site and is considered pathogenic. For the two other
missense mutations, p.Arg295Cys and p.Asp91Asn, no
hard evidence for their pathogenicity is yet available.
What we do know is that none of the mutations in this
study was present in the 200 control chromosomes we
examined. Furthermore, Sieber et al. (2003) reported the
p.Arg295Cys mutation in a patient with three colorectal
209
adenomas, and the p.Asp91Asn mutation has been re-
ported once in a patient with colorectal cancer and 30
adenomas (Nielsen et al. 2005), indicating that these two
missense mutations might be pathogenic.
Of course one might also question the pathogenic
nature of the four MMR missense variants that are
found in combination with an MUTYH mutation. The
MSH2 p.Ile577Thr and the MSH6 p.Pro1087Ser
mutations have not been reported before, and we de-
tected the latter in an other patient with colorectal
cancer at age 36 (data not published). Alternative amino
acid substitutions at this residue have been described
(Wijnen et al. 1999) (http://www.insight-group.org). The
pathogenicity of missense mutations is diﬃcult to
establish, even with help of functional assays. For
example, Kolodner et al. performed a S. cerevisae-based
assay to assess the pathogenicity of the MSH6
p.Ser144Ile missense mutation, and suggested that this
mutation might be pathogenic (Kolodner et al. 1999). In
contrast, in an in-vitro MMR assay that studied the
ability of the mutant proteins to form MSH2-MSH6
heterodimers, the same MSH6 mutation appeared as
functional as the wild type (Kariola et al. 2002). Some
mutations we found may eventually turn out to be
harmless polymorphisms. For instance, the MSH6
p.Leu396Val mutation has been reported not only in
cancer patients, but also in healthy controls (Wijnen
et al. 1999) and was not considered pathogenic in a
functional assay (Kolodner et al. 1999). However, it is
conceivable that a missense mutation on its own has
little or no eﬀect, but that it can signiﬁcantly contribute
to cancer risk in the presence of germline mutations in
other genes.
We compared the MUTYH mutation frequency in
the two groups of mutation carriers with the MUTYH
mutation frequency in cancer patients without MMR
mutation and with the 1.5% mutation frequency re-
ported for controls. TheMUTYHmutation frequency in
the group of cancer patients without MMR mutation
turned out to be not signiﬁcantly diﬀerent from the
frequency in healthy British controls. In the former
group, we expected the MUTYH mutation frequency to
be similar or (somewhat) higher than in the normal
British and Dutch population. Given the fact that there
is presently no evidence to suggest a protective eﬀect of
MUTYH mutations against cancer, we have no reason
to assume that the frequency in the normal Dutch
population will be signiﬁcantly higher than in Dutch
cancer patients.
As co-occurrence of MMR gene missense mutations
andMUTYHmutations might be a matter of chance, and
considering the idea that probably most MSH6 (mis-
sense) mutations alone are not strongly promoting CRC
development, one would expect the co-occurrence of both
mainly in sporadic cancers. In fact, none of the ﬁve pa-
tients with a MUTYH and an MMR gene missense
mutation were from an Amsterdam II positive family and
two of the ﬁve patients had a negative ﬁrst degree family
history for HNPCC-associated tumours. One of the ﬁve
patients with a MUTYH and an MMR gene missense
mutation had an MSI-high tumour. Although this might
suggest that MMR deﬁciency did not underlie tumour
development in four of these ﬁve patients, three of these
four patients carried a MSH6 mutation and pathogenic
MSH6 germline mutations are known to be associated
with lower rates of microsatellite instability than germline
Table 3 Combinations of an MUTYH mutation and an MMR gene mutation occurring in individual patients
Patient Gene Exon Nucleotide change Codon Change Cancers/age
of diagnosis
FH/ACII MSI IHC analysis
MLH1/MSH2/MSH6
Group I
1. MUTYH 7 A ﬁ G at 493 165 Tyr ﬁ Cys BL/56 / H +/NI/




2. MUTYH IVS1 G ﬁ A at 36+1 Splice defect CRC/52 / L /+/+
MSH2 11 T ﬁ C at 1729 577 Ile ﬁ Thr CRC/65
3. MUTYH 7 A ﬁ G at 494 165 Tyr ﬁ Cys CRC/47 +/ L +/+/+
MSH6 4 C ﬁ G at 1186 396 Leu ﬁ Val
4. MUTYH 10 C ﬁ T at 883 295 Arg ﬁ Cys CRC/48 / L +/+/+
MSH6 2 G ﬁ T at 431 144 Ser ﬁ Ile
5 MUTYH 10 C ﬁ T at 883 295 Arg ﬁ Cys CRC/39 +/ L +/+/+
MSH6 5 C ﬁ T at 3259 1,087 Pro ﬁ Ser
6. MUTYH 13 G ﬁ A at 1145 382 Gly ﬁ Asp END/45 +/ H +/+/+
MSH6 2 G ﬁ T at 431 144 Ser ﬁ Ile
Group III
7. MUTYH 3 G ﬁ A at 271 91 Asp ﬁ Asn CRC/64 / L NA/NA/NA
CRC/69
Group I: 40 carriers of a truncating MMR gene mutation (14MLH1, 21MSH2, 5MSH6); Group II: 36 carriers of a missense MMR gene mutation
(11 MLH1, 5 MSH2, 20 MSH6); Group III: 134 cancer patients without an MMR gene mutation
CRC colorectal cancer; END endometrial cancer; BL bladder cancer; FH positive ﬁrst degree family history for HNPCC associated tumours; ACII
Amsterdam II positive; MSI microsatellite instability; H high; L low; IHC immunohistochemistry; NI not interpretable; NA not analysed
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mutations in other MMR genes (Kolodner et al. 1999;
Berends et al. 2002). From a theoretical point of view, the
MSH6 and MUTYH mutations might also have jointly
impaired base-excision repair or impaired apoptosis sig-
nalling, a process that has been linked to MMR gene
function (Fishel 2001).
Our ﬁndings seem to be contradictory to the study
recently published by Ashton et al. (2005). They per-
formed a similar study, in which they compared the
MUTYH mutation frequencies in 233 MMR mutation
negative and in 209 mutation positive HNPCC patients.
They detected ﬁve heterozygous MUTYH mutations in
the former and two in the latter group. There was no
statistical diﬀerence in MUTYH mutation frequency
between the two groups. However, we cannot compare
their results with ours in all details, as for example, no
MSH6mutation carriers were included in their study, no
subgroup analysis of truncating and missense MMR
gene mutation carriers was presented, and instead of full
MUTYH gene analysis, only the frequencies of the two
most common mutations were determined.
In conclusion, we present the statistical observation
that MUTYH mutations occur more frequently in
MMR gene missense mutation carriers than in controls.
Our preliminary results suggest that the presence of a
monoallelic MUTYH mutation combined with a mis-
sense MMR gene mutation, of MSH6 in particular,
leads to an increased cancer risk. As the possible inter-
action of the observed missense mutations is presently
unknown at the functional level, we cannot reach any
deﬁnite conclusions yet as to its clinical signiﬁcance.
However, if larger studies conﬁrm these results, then this
might have implications for management of patients
with monoallelic MUTYH mutations. They should all
be examined for mutations in MSH6 and conversely,
MSH6 missense mutation carriers should all be screened
for MUTYH mutations.
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